New eczema drug candidate tested in healthy chinese volunteers
NCT ID NCT06214481
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a single dose of the experimental drug rocatinlimab in 20 healthy Chinese adults. The main goal was to see how the drug moves through the body and whether it is safe. This is a first step toward possibly using the drug to treat atopic dermatitis (eczema) in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rocatinlimab (AMG 451)
- What this could lead to
- If successful, this study could provide dosing and safety data needed to test rocatinlimab as a potential treatment for atopic dermatitis in Chinese patients.
- What could go wrong
- This is an early, small study in only 20 healthy people, not patients. It is designed to measure drug levels and safety, not to test if it works for the disease. Side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huashan Hospital Affiliated to Fudan University?
Shanghai, 200040, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection calm severe eczema when creams fall short?
- Can a new biologic calm severe eczema?
- Can a daily probiotic soothe colicky babies and calm eczema?
- Can a new injection match an existing eczema treatment?
- Can Real-World data unlock better skin disease care?
- Can a meditation app soothe teen eczema?